Recipharm and Pharmanest Form Collaboration
News Jul 04, 2014
Recipharm Karlskoga AB and Pharmanest AB have announced the formation of a new pharmaceutical manufacturing contract for SHACT.
Every year, millions of women around the world experience pain and discomfort during IUD insertion (intrauterine contraception). There are few treatment options with proven efficacy and safety available to these women.
SHACT is a product based on an innovative formulation of lidocaine, a well-known anesthetic, and a proprietary application device developed to simplify topical application in the cervix and uterus.
SHACT has demonstrated convincing Phase II efficacy data as local anesthesia in connection with IUD insertion and also recently reported positive data from a hysteroscopy study.
Recipharm and Pharmanest have reached a milestone in their existing collaboration and Pharmanest is now preparing its candidate SHACT for launch.
Additionally, the companies have reached a long term agreement for commercial manufacturing, with the precise product launch date to be announced later.
Jointly, the two companies will offer commercial supply to any market that Pharmanest determine to enter for supply and sales of their first pharmaceutical product SHACT.
Ingela Palmkvist, General Manager at Recipharm in Karlskoga, commented: “I really look forward to closely following the introduction of this product to various markets. Indeed, I believe it will make a highly significant difference to patients.”
Gunilla Lundmark, CEO at Pharmanest said: “I am very pleased that Pharmanest and Recipharm have entered into this new collaboration following the product development success achieved to date. Given the strong clinical data we are now rapidly moving toward commercialization. We look forward to working closely with Recipharm for the commercial manufacture of the product and, indeed, to pooling our respective skills and capabilities to supply the pharmaceutical product to key target markets.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
New Research Hub to Tackle Global Vaccination ChallengesNews
The University of Bristol will contribute to a new research hub to increase global immunisation coverage and improve response to viral outbreaks through the rapid and cost-effective deployment of vaccines.READ MORE